Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TR-701 di- salt · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| free acid | EXPERIMENTAL | TR-701 free acid phosphate powder in capsule formulation (equivalent to 150 mg TR-700) |
| di-sodium phosphate salt | EXPERIMENTAL | One 200 mg capsule of TR-701 di-sodium phosphate salt (equivalent to 150 mg TR-700) |
| Name | Type | Description |
|---|---|---|
| TR-701 di-sodium phosphate salt | DRUG | One 200 mg capsule of TR-701 di-sodium phosphate salt (equivalent to 150 mg TR-700) |
| TR-701 free acid phosphate | DRUG | One 182 mg capsule of TR-701 free acid phosphate (equivalent to 150 mg TR-700) |
Inclusion Criteria: * In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG, and vital signs; * Females will be non-pregnant, non-lactating, and either postmenopausal for at least 1 year, surgically sterile for at least 90 days, or ...
TR-701 di-salt is an investigational small molecule being developed by Merck & Company, Inc. (MRK). It is currently in Phase 1 clinical development. The drug has been studied in healthy volunteers, with one completed trial involving 12 participants.
TR-701 di-salt is being studied for use in healthy volunteers. The completed Phase 1 trial was an exploratory pharmacokinetic and bioavailability study of two capsule formulations of torezolid phosphate. The drug is still in early clinical development and is not approved for any medical condition.
TR-701 di-salt is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company is conducting clinical trials to evaluate the drug's pharmacokinetics and bioavailability in healthy subjects.
TR-701 di-salt is in Phase 1 clinical development. The drug is investigational and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and no active trials are currently listed.
TR-701 di-salt has one completed clinical trial, NCT00876655, titled "Exploratory Pharmacokinetic and Bioavailability Study of 2 Capsule Formulations of Torezolid Phosphate." This Phase 1 study enrolled 12 healthy volunteers in the United States and was controlled and biomarker-selected.